775-Rewiring STAT Signaling with Trikine Immunotherapeutics
Researchers have developed a novel class of engineered cytokine agonists called Trikines to overcome the limitations of natural immune signaling. By compelling the assembly of three-chain receptor complexes, these molecules allow scientists to customize cellular responses by activating specific combinations of STAT transcription factors. This "mix-and-match" strategy creates bespoke signaling outputs that can promote beneficial immune traits, such as T cell stemness and survival, without the systemic toxicity often associated with traditional cytokine therapies. Pre-clinical models…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.